#tracon 2022

[ghoku]

the hilarious world of Tirooon Jokes, where controllers take silliness and fun to a whole new level! Picture this: when the operator asks a pilot and say "TIRON?" and like clockwork, at least two other people respond in the background like a PARROT BIRD with an enthusiastic "TIROOOOON!!" It doesn't stop there, though.aviation humor It's an ongoing cycle of banter and playful teasing that never fails to bring smiles to our faces.🤣😂😆 Must watch: https://www.youtube.com/playlist?list=PL2Ht100hWtXTx2YhGYVFHejldUeNIcJ2l https://www.youtube.com/playlist?list=PL2Ht100hWtXSFB-KhJwrBI67JMmWDnBM-

[choochooboss]

Sketch dump! Vol. 5

September 2022 (Part 1/2)

The first piece on top summarised my cosplay rush for Tracon 2022! The second is an old idea for a charm.

"SURPRISE!!"

Back in 2022 I hosted an art raffle for reaching 777 followers on Twitter! The winner would get their submas themed idea realised (which was their friends throwing a surprise party for the twins!). I wanted to make a little comic and have the bosses walk in their office where depot agents, Elesa, Drayden, Skyla, Clay etc. would be waiting with decorations and treats and games.

Emmet is all smiles of course while Ingo gets so emotional he could only whisper a "super bravo".

Not really headcanons anymore but still funny ideas.

1. Emmet gets clumsy when off-rhythm! He starts walking in curves if there is nobody else around to match his rhythm with.

2. Emmet spaces out/forgets to say things aloud when someone speaks too long or when things go off-script! His thinking gets interrupted easily.

3. Ingo sometimes bumps into doors because he is too used to automatic doors!

4. When things go off-script Ingo speaks too much and rushes in straight lines"

Also my little inexpensive sketchbook & my trusty tools! Mechanical pencil and eraser pen are life when scribbling my skrimblos smaller than a postage stamp!

More Ingo~ I utilise a wide range of sources for references, including CSP's poseable 3D models, they can come really handy with perspectives and proportions!

The second piece is my very first attempt at cosplay in Tracon 2022: Blingo! I walked in with a sequin hat, leather jacket, leather pants and high heel patent leather boots.

The hardest part of cosplaying Ingo is remembering NOT to smile ahaha!

Some hairstyle tests

I drew these for a huge submas art collaboration over Twitter hosted by @/mimizukeii!! It was technically my first art collab before I started arranging them myself with Aggie/Magma.

While looking for train related songs I found this cute nursery rhyme to go with the marching:

"Over the mountains,

Over the plains,

Over the rivers,

Here come the trains.

Carrying passengers,

Carrying mail,

Bringing their precious loads In without fail"

I wanted to compare these silly twins, planning to do something more silly with them later. Also a sketch of @/fukurow's butler designs I never finished.. The capes compliment them so well, I love them!!

Prequel to this piece! Emmet is so confident in himself he thinks Pierce wants to learn from him but is invited for a duet on the stage instead!!

Emmet has really great voice actors in Pokemas! I especially love how his english VA gives him that bri'ish/posh/sophisticated vibe while also soft and melodic! I know for SURE this VA/Emmet can sing, I can show you later!

One of my favourite sketches!! I wanted to add a bunch of characters in the BG reacting to this sonic blast of emotion over a performance!

Heyyy it's the smile buddies comic!! I really hope Ingo gets to interact with Marnie in Pokemas one day!!

I feel Ingo's eyes in the mirror panel is a little off in the final comic, I meant to keep it softer like in the sketch!

It's Nimbasa trio!! Idea inspired by submas EX uniform colors. Might continue this later!

Some BG tests for this piece! Compositing is hard but absolutely worth the effort, it can make a huge difference in the appeal of your piece!!

Practise piece drawing over a photo I thought was cool! I want to get more experimental with lighting and perspective!

'How's it hanging bro?' Who hung him up there anyway??

Sketch for this arguing scene! Something REALLY BAD needs to happen for them to end up that tense! Even if I want to present them close to the canon material I still want to put them in really challenging situations to see how far I can push their emotions!

Thank you so much for coming all the way down here!! This set was pretty loaded, I hope you enjoyed scrolling through all this ahah!

Previous posts:

Sketch dump Vol. 1: April-June 2022

Sketch dump Vol. 2: July 2022

Sketch dump Vol. 3: August 2022

Sketch dump Vol. 4: July 2022 Part 2

[retadoesthings]

Sawamura Haruka from Yakuza 5 Cosplay handmade and worn by @retadoesthings Photographed by Jasu (1) & Erika Lampi (2) Nordic Cosplay Championships preliminaries, Tracon 2022, Finland

The road to Haruka 2.0 starts here. 🌸

This is how my idol!Haruka costume looked on stage last fall. I’ve taken a break from her and worked on other things in the meantime, but now I’m slowly getting back on this particular horse. I’ve gone through all the parts and stared at the reference images again and made a list of things I want to improve. Next up: putting in the actual work.

I’ve heard there are some technical requirements about the performances in the NCC finals I need to take into account though... I hope I get to maintain the skit the way it was. I’m very fond of it. There are a lot of different skills I’ve used while creating my skit, plus a whole lot of heart involved.

[nu--ephedrin]

Wuffelipuffeli Guilty Solo! | Tracon 2022

[delveinsight12]

Soft Tissue Sarcoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc.

DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Soft Tissue Sarcoma, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Soft Tissue Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Soft Tissue Sarcoma Market Forecast

Recent breakthroughs in the Soft Tissue Sarcoma Market:

In October 2022, LIXTE Biotechnology Holdings, Inc. disclosed that the Spanish Agency for Medicines and Health Products (AEMPS) had authorized a Phase 1b/randomized Phase 2 study involving LB-100, the company's primary clinical compound, combined with doxorubicin compared to doxorubicin alone, the established global standard for initial treatment of advanced soft tissue sarcomas (ASTS).

In September 2022, Immutep Limited announced the signing of a Material Transfer Agreement ("Agreement") with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. This Agreement enables an investigator-initiated open-label Phase II clinical trial to assess Immutep's lead product candidate, efti, in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) involving up to 40 patients with selected soft tissue sarcomas (STS).

In September 2022, TRACON Pharmaceuticals, Inc. revealed that the U.S. Food and Drug Administration (FDA) had granted fast-track designation for the development of envafolimab (KN035) for patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who had progressed on one or two prior lines of chemotherapy.

In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for the treatment of soft tissue sarcoma. AVA6000 is a modified form of the chemotherapy drug doxorubicin, utilizing the pre|CISION technology to predominantly activate within the tumor, aiming to enhance safety, tolerability, and efficacy while sparing healthy tissue exposure.

In May 2022, Immix Biopharma, Inc., reported positive interim study data demonstrating that after one cycle of treatment, the company's lead candidate IMX-110 resulted in 75% survival compared to 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. IMX-110 was evaluated against approved drugs for STS treatment, with Trabectedin administered according to Meco et al., 2003 (trabectedin monotherapy treatment arm), and IMX-110 at a dose of 2.0 mg/kg.

In April 2022, Telix Pharmaceuticals Limited announced a licensing agreement with Eli Lilly and Company ("Lilly") granting Telix exclusive worldwide rights to develop and commercialize radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial focus will be on a rare cancer type known as soft tissue sarcoma (STS).

Some of the key facts of the Soft Tissue Sarcoma Market Report: 

The Soft Tissue Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

According to the revised statistical estimates of the American Cancer Society (2022), there were about 13,190 newly diagnosed cases of soft tissue sarcoma and approximately 5,130 deaths (2,740 males and 2,390 females) due to soft tissue sarcoma in the US. 

Key Soft Tissue Sarcoma Companies: Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others

Key Soft Tissue Sarcoma Therapies: Camsirubicin, Lurbinectedin, Liposomal Annamycin (L-Annamycin), AL3818, YH001, CFT8634, Olaratumab + Doxorubicin, Tazemetostat + Doxorubicin HCl, Niraparib, Seclidemstat, Tinostamustine (EDO-S101), HFB301001, Tigilanol Tiglate, Pembrolizumab, Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy, L19TNF and DOXORUBICIN, doxorubicin with AGEN1884 and AGEN2034, APX005M, MGCD516, and others

The Soft Tissue Sarcoma epidemiology based on gender analyzed that Males are slightly more affected in the case of Soft Tissue Sarcoma

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Soft Tissue Sarcoma pipeline products will significantly revolutionize the Soft Tissue Sarcoma market dynamics.

 Soft Tissue Sarcoma Overview

Soft tissue sarcoma is a relatively uncommon form of cancer that originates in the soft tissues of the body, including muscles, tendons, fat, blood vessels, and nerves. While it can affect individuals of all ages, it is more frequently diagnosed in adults. The precise causes of soft tissue sarcoma are not always clear, though certain risk factors have been identified, such as exposure to radiation, specific genetic conditions, and previous treatment with certain chemotherapy drugs.

The symptoms of soft tissue sarcoma can vary depending on the size and location of the tumor. Common indicators may include the presence of a noticeable lump or swelling in the affected area, pain or tenderness, restricted mobility, and sometimes a sensation of pressure or fullness. Since these symptoms can resemble those of various other conditions, it is crucial to seek medical attention if they persist or worsen.

The diagnosis of soft tissue sarcoma typically involves a combination of imaging techniques such as MRI, CT scans, and ultrasounds to identify the presence and location of the tumor. Following this, a biopsy is performed, in which a small tissue sample is extracted and examined under a microscope to ascertain whether the growth is malignant or benign.

Get a Free sample for the Soft Tissue Sarcoma Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market 

Soft Tissue Sarcoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Soft Tissue Sarcoma Epidemiology Segmentation:

The Soft Tissue Sarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Soft Tissue Sarcoma Incident Cases 

Soft Tissue Sarcoma Gender-specific Incident Cases 

Soft Tissue Sarcoma Type-specific Incident Cases 

Soft Tissue Sarcoma Age-specific Incident Cases 

Soft Tissue Sarcoma Stage-specific Incident Cases 

Incident Cases of Soft Tissue Sarcoma by Extremities 

Download the report to understand which factors are driving Soft Tissue Sarcoma epidemiology trends @ Soft Tissue Sarcoma Epidemiology Forecast

Soft Tissue Sarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched during the study period. The analysis covers Soft Tissue Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Soft Tissue Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Soft Tissue Sarcoma Therapies and Key Companies

Camsirubicin: Monopar Therapeutics

Lurbinectedin: Jazz Pharmaceuticals

Liposomal Annamycin (L-Annamycin): Moleculin Biotech, Inc.

AL3818: Advenchen Laboratories, LLC

YH001: Tracon Pharmaceuticals Inc.

CFT8634: C4 Therapeutics, Inc.

Olaratumab + Doxorubicin: Eli Lilly and Company

Tazemetostat + Doxorubicin HCl: Epizyme, Inc./Ipsen

Niraparib: GlaxoSmithKline

Seclidemstat: Salarius Pharmaceuticals, LLC

Tinostamustine (EDO-S101): Mundipharma Research Limited

HFB301001: HiFiBiO Therapeutics

Tigilanol Tiglate: QBiotics Group Limited

Pembrolizumab: Merck Sharp & Dohme LLC

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy: Polaris Group

L19TNF and DOXORUBICIN: Philogen S.p.A.

doxorubicin with AGEN1884 and AGEN2034: Agenus Inc

APX005M: Apexigen America, Inc.

MGCD516: Mirati Therapeutics Inc.

Discover more about therapies set to grab major Soft Tissue Sarcoma market share @ Soft Tissue Sarcoma Treatment Landscape 

Soft Tissue Sarcoma Treatment Market

Treatment for soft tissue sarcoma is typically personalized, taking into account factors such as the tumor's type, location, stage, and the patient's overall health. The primary methods of treatment include surgery, radiation therapy, and chemotherapy, which may be used alone or in combination, depending on the specific circumstances. Surgery is often the first-line treatment for localized soft tissue sarcoma, aiming to excise the tumor along with a margin of healthy tissue to reduce the risk of recurrence. In some cases, reconstructive procedures may be necessary to preserve function and appearance.

Radiation therapy involves using high-energy rays to target and eliminate cancer cells or shrink tumors, either before surgery to make the tumor more manageable or as a standalone treatment for tumors that cannot be operated on. It may also be employed post-surgery to lower the risk of local recurrence. Chemotherapy may be recommended for certain types of soft tissue sarcomas that are prone to metastasis. This treatment entails the use of drugs to kill or slow the growth of cancer cells and is typically administered in cycles to allow for recovery between sessions.

In recent years, targeted therapies and immunotherapy have emerged as promising avenues for treating soft tissue sarcomas, particularly in cases where traditional treatments have been ineffective. These innovative treatments are designed to specifically target molecules involved in tumor growth or stimulate the body's immune system to combat cancer cells. A multidisciplinary team comprising oncologists, surgeons, radiation oncologists, and other specialists collaborates to devise the most suitable treatment plan for each patient. Regular follow-ups and monitoring are essential to detect any signs of recurrence or potential treatment-related side effects. Although treating soft tissue sarcoma can be challenging, ongoing advancements in medical research and personalized treatment approaches offer hope for improved outcomes and enhanced quality of life for affected individuals.

To know more about Soft Tissue Sarcoma companies working in the treatment market, visit @ Soft Tissue Sarcoma Clinical Trials and Therapeutic Assessment

[jackyquickpooppostings]

from tracon 2022

[technewspoint]

Malignant Fibrous Histiocytoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies – Tracon Pharmaceuticals, Actuate Therapeutics, Novartis,

http://dlvr.it/Sn0wG1

[blackboard-monitor]

Tracon 2022 Saturday (part 2)

@fairandcruel as Caleb Widogast @oinanibakamite as Jester Lavorre myself as Essek Thelyss

photography by @rinkamari

not pictured: me falling ass first into the flowerbed

[philonob]

I’ll be on Tracon 2022 Art Alley this weekend! If you’re attending come say hi!

[pawweh]

Hello here is my Soundwave cosplay from Tracon 😎

[shinonart]

Thank you for yet another amazing Tracon! I had a blast and I’m so happy with my table setup as well. A bunch of things sold out and I’m still in progress of doing my inventory so I can update my Etsy shop!

[konotte]

Naruhodou enjoying cream soda 😋🌸✨

(the only photo ((that I'm somewhat happy with)) taken at Tracon 2022)

[retadoesthings]

My cosplays from 2022-2023

Click the character's name to find related posts.

2022

AE3803 from Cells at Work! Photo by Santtu Pajukanta Costume made for a stage show; compiled by me & the show team.

Sawamura Haruka from Yakuza 5 Photo by Tamameru Costume made by me. Used in Nordic Cosplay Championship preliminaries in Tracon 2022 (1st place).

2023

Tsukimi Eiko from Paripi Koumei / Ya Boy Kongming Teppo/Isperia as Koumei/Kongming Photo by Raaputtaja Costumes made by me and Isperia.

Retoree from Show by Rock!! Nani as Cyan Photo by Nyymix Costumes made by me and Nani. Used in Assembly Winter 2023 cosplay competition.

Sawamura Haruka from Yakuza 5 Photo by Allion Photography Costume made by me, updated for the finals. Used in Nordic Cosplay Championship finals in Närcon 2023.

Jacqueline from Show by Rock!! Photo by me Costume made by me.

[marukokris]

More Tracon photos :D . We also did a couple cosplay with @jeanoiz as Joseph and Caesar from Jojo's Bizarre Adventure: Battle Tendency . It was fun to cosplay as these two dorks <3. It's a shame we didn't get a chance to took so many proper photos but maybe some other time.

First photo was taken by Aelleia ( twitter: aenilithil , instagram: aelleia_ )

[neuvostoliitto]

Sunnuntaina Traconissa pitämässä luentoa meidän rakkaasta robo blorbosta @jalkakaneli n kanssa. Tulkaa katsoon!!

[eurobeat-pics-that-go-hard]